COMMUNIQUÉS West-GlobeNewswire

Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
21/04/2026
First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset entering a Phase I [...]
Groundbreaking approaches such as cell therapies on the horizon for transformation of neural hearing loss, Rinri Therapeutics’ review1 shows
21/04/2026
Elevating the importance of neural health via better diagnosis and treatment is crucial for restoration of natural hearing, JARO review concludes Sheffield, UK, April 21, 2026 (GLOBE NEWSWIRE) -- The role of neural [...]
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
21/04/2026
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE) If approved, Gazyva/ [...]
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
21/04/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Rapid Nutrition Establishes Flagship Platform to Strengthen Multi-Channel Strategy in Australia
21/04/2026
Expected to generate additional revenue through product sales and supplier-funded activation programmes LONDON, April 20, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech [...]
SnoreRX Anti-Snoring Mouthpiece Claims Evaluated: Doctor-Recommended Adjustable Mouthguard for Safer Airway Breathing Overnight
21/04/2026
SnoreRX examines its FDA-cleared mandibular advancement mouthpiece design, 1-millimeter adjustable calibration, boil-and-bite custom fitting process, 30-day guarantee terms, pricing structure, and what consumers should [...]
TRT UK - What Is TRT and Who Should Take a TRT Test? A Complete UK Guide
21/04/2026
Rising Interest in TRT UK: What Current Medical Guidance Says About Symptoms, Testing, and Access to Treatment Hampshire, England, April 21, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This content is provided for [...]
Enjoin Launches Technology-First Rebrand For Scalable Revenue Integrity
21/04/2026
Enjoin, a clinically intelligent revenue optimization platform for health systems, announced a refreshed brand identity reflecting continued investment in workflow-driven technology, advanced analytics, and clinical [...]
Moonbuddy Kids Breathing Guidance Under Investigation: Tactile Breathwork Device Claims Get Reviewed
21/04/2026
A 2026 informational overview of Moonbuddy's screen-free calming device for children, slow-paced breathing research context, 4-minute sleep support claims, parasympathetic activation positioning, pricing structure, and [...]
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
20/04/2026
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half [...]
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
20/04/2026
Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and development of novel [...]
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
20/04/2026
WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary [...]
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
21/04/2026
Company Marks First Annual Meeting at Historic Perkins Place Office Building as It Prepares to Relocate Its Headquarters from First Horizon Plaza Tower KNOXVILLE, Tenn., April 20, 2026 (GLOBE NEWSWIRE) -- Provectus [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
20/04/2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49,358 shares of [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/04/2026
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase [...]
NADP appoints first dentist to lead dental informatics program
20/04/2026
Dr. Lauren E. Gritzer named dental informatics and plan operations director DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- The National Association of Dental Plans has appointed Lauren Gritzer, DDS, MPH, as director of [...]
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
20/04/2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
20/04/2026
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定，并通过 IND 审评
21/04/2026
FDA 授予 Daretabart (hu1418K322A) 快速通道认定资格，以解决高危神经母细胞瘤领域存在的重大未满足医疗需求，允许该药物进入加速评审和滚动审评流程 FDA 通过新药临床研究 (IND) 申请后，即可在高危神经母细胞瘤复发及难治性患者中启动 SHINE II/III 期临床试验 Daretabart (hu1418K322A) 第一个商业化规模 GMP 生产批次已顺利完成项目基于 II 期的积极数据， [...]

Pages